Skip to main content
Premium Trial:

Request an Annual Quote

This Week in JAMA: May 2, 2012


In JAMA this week, researchers at the University of Texas MD Anderson Cancer Center and the University of Chicago report on the effects of brachytherapy versus whole-breast irradiation and subsequent mastectomy on the survival of older women with invasive breast cancer. The team retrospectively studied 92,735 women aged 67 and older with invasive breast cancer, 6,952 of whom were treated with brachytherapy after lumpectomy and 85 of whom were treated with whole-breast irradiation. The team found that the women treated with brachytherapy had a higher five-year incidence of subsequent mastectomy than the women treated with whole-breast irradiation. Further, brachytherapy was associated with more frequent infectious and non-infectious post-operative complications than whole-breast irradiation. Five-year overall survival rates were similar, however — 87.66 percent in patients treated with brachytherapy versus 87.04 percent in the whole-breast irradiation group. "In a cohort of older women with breast cancer, treatment with brachytherapy compared with WBI was associated worse with long-term breast preservation and increased complications but no difference in survival," the authors write.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.